Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
A legfontosabb adatok
- Ki végzi
- Yale University
- Hol
- New Haven (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Fut, nem toboroz
- Fázis
- 1. fázis
- Résztvevők
- 4 fő vett részt
- Kezdés
- 2026. márc. 26.
- Várható befejezés
- 2027. febr.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- Semaglutide 1.0 mg
- A regiszteradat frissítve
- 2026. szeptember 10.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up)
- Age 18 and older
- Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg/m2
- Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years
- Meet current DSM-5 criteria for Alcohol Use Disorder
- Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators
- Read, comprehend, and write English at a sufficient level to complete study-related materials
- For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation
Ki nem vehet részt
- Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening
- Is currently using other medications for weight loss or other GLP-1 receptor agonists
- Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device
- History of malignant neoplasms within the past 5 years prior to screening
- Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2
- Has a history of allergy or sensitivity to Semaglutide
- Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
- Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute
- Has current uncontrolled hypertension
- Has current uncontrolled Type I or Type II diabetes mellitus
- Has active gallbladder disease
- Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder
- Has a recent history of substance use disorder (with the exception of cannabis or tobacco use disorder) within the past 12 months
- Is currently engaging in other treatment for Alcohol Use Disorder or making intentional efforts to quit alcohol use
- Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria which, in the investigator's opinion, might have jeopardized the participant's safety or compliance with the protocol
- Has untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit
- History or presence of chronic or recurrent pancreatitis
- Is breast-feeding, pregnant, or not using a reliable form of birth control
- Reports active suicidal or homicidal ideation
Helyszínek itt: Egyesült Államok
- Yale School of MedicineNew Haven, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.
A vizsgálat 2 csoportja
- SemaglutideA vizsgált kezelés
Participants randomized to Semaglutide will be initiated on a 0.25 mg dose (injection) once weekly for 4 weeks (first month) with an escalation to 0.5 mg for the second month, and 1.0 mg in the final month. Participants will be on Semaglutide for three months total.
Kezelés: Semaglutide 1.0 mg
- Wait-list controlNincs vizsgálati kezelés, összehasonlításként
Participants randomized to wait-list control will be followed for three months but no treatment will be administered. At the conclusion of the study, participants in the wait list control group will be offered a three-month behavioral intervention to treat Alcohol Use Disorder, although this is not required.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Semaglutide Treatment for Alcohol Use Disorder After Metabolic and Bariatric Surgery: A Pilot Randomized Controlled Trial
- A regiszteradat frissítve
- 2026. szeptember 10.